A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstroâ„¢ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2009
This was a multicenter, open-label, randomized, crossover trial in subjects with MS who were already taking a stable dose of baclofen (up to 80 mg/day) for spasticity. The trial was designed to assess subject preference for Kemstro or conventional baclofen. At Visit 1, subjects were screened, and if qualified, were randomly assigned to one of two following treatment sequences: Kemstro/conventional baclofen or conventional baclofen/Kemstro.
Epistemonikos ID: 0bf5ee303deccef11c1ab5dd2d2ce461d70122f9
First added on: Mar 31, 2022